BioNexus Gene Lab Corp faces delisting from Nasdaq due to not meeting the minimum bid price requirement, but has requested a hearing to appeal this decision while appointing new directors to strengthen governance.
AI Assistant
BIONEXUS GENE LAB CORP
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.